News | January 07, 2023
Dabur India expects low to mid-single digit revenue growth for Q3 FY23
International Business is expected to post double-digit revenue growth during the quarter in constant currency.
International Business is expected to post double-digit revenue growth during the quarter in constant currency.
Zydus is the first company to receive final approval and launch Topiramate Extended-Release Capsules, USP 25 mg, 50 mg, and 100 mg in the United States.
ANSSI Wellness launches Asia’s premier and USA-patented ‘Spinal Decompression Treatment’ center in Nashik
Partnership to leverage the Helix Laboratory Platform and QIAGEN's biopharma relationships, NGS capabilities, and global regulatory expertise
Purchase agreement with ViewRay will make state-of-the art precision radiation therapy available in China
The PharmaEssentia Innovation Research Center (PIRC) will advance the company’s diverse pipeline and research footprint in the U.S., driving job creation
Acquisitions have the potential to add at least $1 billion in sales by 2028
Honan will lead the company in identifying and executing acquisitions that complement Emmes’ existing strong federal government client base, expand its biopharma portfolio, enhance its technology offerings, and broaden its global reach
The collaboration with IIT Kanpur will build on this foundation and expand the domain of research and development in healthcare technology
Over 30 years of deep life sciences industry experience with a wide range of expertise in corporate governance, capital markets, licensing and strategic collaborations
Subscribe To Our Newsletter & Stay Updated
